MD; for the ADRIA InvestigatorsBackground-Supraventricular tachyarrhythmias are the main cause for inappropriate therapy by implantable cardioverterdefibrillators (ICDs). For better rhythm discrimination, an atrial electrogram is helpful and usually obtained from an additional atrial lead, even in the absence of sinus node or atrioventricular nodal disease. An Aϩ-ICD system with integrated atrial sensing rings mounted 15 to 18 cm from the tip of an ICD lead may obviate the need to implant a separate atrial lead. The aim of the study was to compare the novel Aϩ-ICD and a conventional dual-chamber (DR)-ICD. Methods and Results-Two hundred forty-nine patients with standard ICD indications but no requirement for antibradycardia pacing were randomized to receive an Aϩ-ICD (nϭ124) or a DR-ICD (nϭ125). Implantation details, need for ICD system revision, long-term sensing, documented arrhythmia episodes, and the respective rhythm discrimination during follow-up were analyzed. The implantation time was significantly shorter in the Aϩ-ICD group (67Ϯ30 vs 79Ϯ30 minutes, Pϭ0.003). Mean P-wave amplitudes were 3.5Ϯ0.8 mV (Aϩ-ICD) and 3.2Ϯ0.6 mV (DR-ICD) and remained stable during the follow-up period of 12 months. Surgical revision was necessary in 13 patients in the DR-ICD and 10 in the Aϩ-ICD group. All 593 ventricular tachyarrhythmia episodes were correctly discriminated. Sensitivity and specificity of supraventricular tachyarrhythmia discrimination were not different between the study groups. Conclusions-The novel Aϩ-ICD system can be implanted faster and is equivalent to a standard DR-ICD with regard to the detection of ventricular tachyarrhythmias and supraventricular tachyarrhythmias. It represents a useful alternative to obtain atrial sensing. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00324662.